In this scenario, the IDO1 pathway activated in CLL cells by stimuli from other cell types, such as endothelial cells, NLCs, MDSCs, and T cells inside microenvironmental niches, could interfere with the effect of novel targeted drugs currently used for CLL patients’ management. Here, IDO1 is linked to B-cell chronic lymphocytic leukemia.